FIGURE 4.

AEA treatment reduces immune cell migration. Human PBMCs were pre-treated with ethanol (EtOH), Diclofenac and EtOH (Dic), and AEA (10 µM) with Diclofenac (AEA). Medium without (-FCS) and with FCS (+FCS) were used as negative and positive controls. The numbers of migrated cells were measured by flow cytometry and represent three independent experiments. The numbers of live cells (A), leukocytes (B), B cells (C), NK cells (D), CD56dimCD16hi NK cells (E), CD56hiCD16dim NK cells (F), T cells (G), CD4⁺ T cells (H), CD8⁺ T cells (I), CCR6+ CD4⁺ T cells (J), classical monocytes (K), activated mDCs (L), myeloid cells (M), mDCs (N), myeloid CD33low cells (O), CD195+myeloid CD33low cells (P), and intermediate monocytes (Q) was calculated by the ratio of migrated/non-migrated cells and normalized to EtOH. Data are from three independent experiments, with 2 donors each. Each data point corresponds to a single donor (n = 6). Data are shown as mean $\pm$ SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; p-values were calculated using one-sample t-test.